COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has provided an announcement.
Cosmo Pharmaceuticals is actively participating in Digestive Disease Week® 2025 in San Diego, focusing on AI and gastrointestinal drug development. The event serves as a platform for Cosmo to engage with key opinion leaders and potential partners, aiming to strengthen its position in AI-powered endoscopy and GI therapeutics. By convening its AI advisory board, Cosmo demonstrates its commitment to advancing GI care through technology and strategic partnerships, potentially benefiting doctors and patients globally.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a pharmaceutical company focused on revolutionizing healthcare by developing innovative products to address unmet needs. Operating in the fields of Healthtech/AI, dermatology, gastroenterology, and contract manufacturing, Cosmo collaborates with global partners like Medtronic and Sun Pharma for product commercialization and distribution. Founded in 1997, the company is headquartered in Dublin, Ireland, with offices in the USA and Italy, employing approximately 330 people.
YTD Price Performance: -23.97%
Average Trading Volume: 597
Technical Sentiment Signal: Buy
Current Market Cap: CHF814.1M
For detailed information about COPN stock, go to TipRanks’ Stock Analysis page.